drugset / Trial / NCT00398684

Summary

The purpose of this study was to assess the efficacy of a single dose of the drug nevirapine (NVP) given to pregnant women at onset of labor and to their infant 48-72 hours after birth in addition to standard oral zidovudine (ZDV or AZT) prophylaxis for the prevention of mother-to-child transmission of HIV-1.

Timeline

Start
2001-01
Primary completion
—
Completion
2004-06

Outcome

Met primary endpoint

paper in the nevirapine-nevirapine group and 6.3 percent (95 percent confidence interval, 3.8 to 8.9) in the placebo-placebo group (P<0.001). PMID 15247338 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nevirapine Small molecule 6 mg Oral
Subject Nevirapine Small molecule 200 mg Oral